10-Q: PetVivo Holdings Reports Q2 2025 Results, Shows Reduced Losses Amidst Ongoing Commercialization Efforts

Sentiment:

Quarterly Report 14 November 2024 4:00 PM

PetVivo Holdings, Inc. reported its financial results for the quarter ended September 30, 2024, showing a decrease in net losses compared to the same period last year, while continuing to focus on commercializing its lead product, Spryng.

Capital raiseThe company issued 3,045,000 shares of Series A convertible preferred stock in exchange for proceeds of $1,218,000.The company issued 1,889,434 shares of common stock in exchange for proceeds of $1,322,600.The company raised $200,000 of short-term notes from two accredited investors with conversion provisions.The company sold 225,000 restricted common shares to four accredited investors for $112,500.The company expects to continue to raise additional capital through the sale of its securities from time to time for the foreseeable future.

Better than expectedThe company's net loss decreased significantly for both the three and six-month periods compared to the same periods in the previous year, indicating improved financial performance.

Summary

PetVivo Holdings, Inc. reported a net loss of $2.175 million for the three months ended September 30, 2024, a decrease from the $3.661 million loss in the same period of 2023.
The company's revenue for the quarter was $200,720, slightly down from $207,366 in the prior year.
Operating expenses decreased to $2.352 million from $3.129 million year-over-year, primarily due to reduced general and administrative and sales and marketing costs.
For the six months ended September 30, 2024, the net loss was $4.222 million, compared to $6.554 million for the same period in 2023.
The company's revenue for the six-month period was $324,470, consistent with $324,549 in the prior year.
Operating expenses for the six-month period decreased to $4.507 million from $6.128 million year-over-year.
The company's working capital deficit was $611,633 as of September 30, 2024.
PetVivo is focused on commercializing its lead product, Spryng, for the treatment of joint afflictions in animals.
The company has a portfolio of nineteen patents protecting its biomaterials, products, and processes.
The company is also working on a pipeline of additional products for the treatment of animals.

Sentiment

Score: 6

Explanation: The document shows a mixed sentiment. While the company has reduced losses and raised capital, it still faces significant challenges, including a working capital deficit and the need for further funding. The company's future success is dependent on its ability to execute its business plan and raise additional capital.

Positives

The company significantly reduced its net loss for both the three and six-month periods ending September 30, 2024, compared to the same periods in 2023.
Operating expenses decreased substantially due to cost-cutting initiatives in general and administrative and sales and marketing areas.
The company successfully raised capital through the sale of preferred and common stock.
The company continues to commercialize its lead product, Spryng, and has a pipeline of additional products in development.
The company has a strong intellectual property portfolio with nineteen patents.

Negatives

The company's revenue for the three and six-month periods was relatively flat compared to the same periods in the previous year.
The company has a working capital deficit of $611,633 as of September 30, 2024.
The company continues to incur significant losses from operations.
The company is dependent on raising additional capital to fund its operations and commercialization efforts.
A promissory note for $150,000 entered into on September 9, 2024, is in default.

Risks

The company's ability to continue as a going concern is dependent on its ability to achieve profitability and/or obtain adequate financing.
The company faces risks related to the commercialization of its products, including market acceptance and competition.
The company's future success depends on its ability to raise additional capital, which is not guaranteed.
The company is subject to risks related to its manufacturing processes and supply chain.
The company is subject to risks related to legal proceedings, including a threatened lawsuit from a former employee.

Future Outlook

The company expects to continue to raise additional capital through the sale of its securities from time to time for the foreseeable future to fund its business expansion. The company also anticipates growing its product pipeline through the acquisition or in-licensing of additional proprietary products from human medical device companies specifically for use in pets.

Management Comments

Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern.
Management believes in its ability to raise additional funds, but there can be no assurances to that effect.

Industry Context

The company operates in the veterinary market, which is a growing sector with increasing demand for innovative treatments for companion animals. The company's focus on osteoarthritis treatments aligns with the market need for effective solutions for joint afflictions in dogs and horses. The company's product, Spryng, is positioned as an alternative to traditional treatments, which may provide a competitive advantage.

Comparison to Industry Standards

PetVivo's revenue of $324,470 for the six months ended September 30, 2024, is relatively low compared to established veterinary pharmaceutical and medical device companies.
Companies like Zoetis (ZTS) and Elanco (ELAN) report revenues in the hundreds of millions or billions of dollars per quarter.
PetVivo's operating expenses of $4.507 million for the six months ended September 30, 2024, are significant relative to its revenue, indicating a high burn rate typical of early-stage biotech companies.
The company's net loss of $4.222 million for the six months ended September 30, 2024, is also typical of early-stage companies that are investing heavily in research, development, and commercialization.
PetVivo's reliance on distribution agreements with companies like MWI Veterinary Supply Co. and Covetrus is a common strategy for smaller companies to reach a wider market.
The company's focus on a specific niche, such as osteoarthritis treatments for dogs and horses, is a common strategy for smaller companies to gain a foothold in the market.
The company's intellectual property portfolio of nineteen patents is a positive sign for its long-term potential.

Legal Proceedings

David Masters, a former employee, board member, and consultant, has threatened to file suit against the company to recover in excess of $2 million.

Stakeholder Impact

Shareholders are impacted by the company's financial performance and its ability to raise capital.
Employees are impacted by the company's financial stability and its ability to continue operations.
Customers (veterinarians) are impacted by the availability and effectiveness of the company's products.
Suppliers are impacted by the company's ability to pay for goods and services.
Creditors are impacted by the company's ability to repay its debts.

Next Steps

The company plans to continue commercializing Spryng in the United States through its distribution relationships.
The company plans to continue clinical studies to expand its distribution outlets.
The company plans to expand its research and development facilities.
The company plans to grow its product pipeline through acquisitions or in-licensing.
The company may establish strategic out-licensing partnerships to provide secondary revenues.

Key Dates

Date	Description
2007	Spryng completed a safety and efficacy study in rabbits.
2009	The company was incorporated in Nevada.
2014	The company entered its current business through a stock exchange reverse merger.
2017-04	The company acquired Gel-Del Technologies, Inc. through a statutory merger.
2017-05	The company entered into an eighty-four-month lease for office, laboratory, and warehouse space.
2020-01	The company entered into a lease amendment extending the lease term through November 2026.
2020-07-10	The Board of Directors approved the PetVivo Holdings, Inc. 2020 Equity Incentive Plan.
2020-11-05	The company entered into a clinical trial services agreement with Colorado State University.
2021-02	The company established a 401(k)-retirement plan for its employees.
2021-09	The company began commercialization of its lead product Spryng.
2022-01	The company entered into a sixty-three-month lease for office space.
2022-03	The company successfully completed an equine tolerance study.
2022-05	The company began a canine clinical study with Ethos Veterinary Health.
2022-06-17	The company entered into a Distribution Services Agreement with MWI Veterinary Supply Co.
2022-10-14	The stockholders of the company approved the Amended and Restated 2020 Equity Incentive Plan.
2023-01-10	The company entered into a new lease agreement for production and warehouse space.
2023-06	The company began a second canine clinical study with Ethos Veterinary Health.
2023-10	The company entered into a promissory note for $120,000.
2023-11	The company amended the promissory note entered into in October 2023.
2023-12-18	The company entered into a Distribution Services Agreement with Covetrus North America LLC.
2024-02-05	The promissory note and accrued interest from October 2023 was converted into common stock.
2024-03	The company entered into a convertible promissory note for $150,000.
2024-04-10	The company entered into another promissory note for an additional $150,000.
2024-04-29	The noteholder converted the $300,000 principal balance and accrued interest into common shares and warrants.
2024-09-09	The company entered into a convertible promissory note for $150,000.
2024-09-27	The company entered into another promissory note for an additional $350,000.
2024-09-30	End of the reporting period for the quarterly report.
2024-11-14	Date of the quarterly report filing.

Keywords

PetVivo, Spryng, Osteoarthritis, Veterinary, Biomaterials, Medical Devices, Financial Results, Commercialization, Joint Afflictions, Animal Health

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.